Imugene Limited (IUGNF) Stock Price & Analysis
Imugene Limited (IUGNF) — price $0.029 (0.00%), as of the Nov 19, 2026 trading session; market cap $16.1M.
Educational signal · not a buy or sell recommendation · How to read this
Imugene Limited · IUGNF
Imugene Limited is a clinical-stage immuno-oncology company based in Australia, focusing on developing immunotherapies to activate the immune system to fight cancer.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.029 | |
| Change on the day | 0.00% | |
| 52-week range | $0.01 – $0.295 | |
| Market capitalisation | $16.1M | — |
| Shares traded on the day | 10.0K |
Price & events
Other perspectives
Council score for Imugene (IUGNF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 20, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Imugene (IUGNF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Imugene Limited (IUGNF) is the company analyzed here. It employs 14 people and is led by Leslie Chong. In Q4 FY2025 it reported revenue of A$3M and net income of -A$21M. The market values it at $16.1M.
What do the latest results show for Imugene (IUGNF)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of A$3M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | A$3M | -A$21M | -A$0.09 (diluted) |
| Q2 FY2025 | A$1M | -A$48M | -A$0.22 (diluted) |
What are the financial strengths and risks for Imugene (IUGNF)?
Short answer · as of
The distress and quality screens read Altman Z -36.55 · Piotroski F 2. Trailing ratios: current ratio 0.70.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -36.55 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Imugene (IUGNF)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.66M · EPS -0.12 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q4 FY2025) was filed Jun 30, 2025 — 8 months ago.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $1.66M
- EPS estimate
- $-0.12
Measured against a quoted price of $0.029 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held IUGNF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported IUGNF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Imugene Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the IUGNF research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is IUGNF a good stock to buy?
Stock Expert AI does not rate IUGNF buy, sell or hold. Imugene Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the IUGNF stock price today?
The last price recorded for Imugene Limited (IUGNF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for IUGNF?
The main risks for Imugene Limited include the potential for clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies. The company also faces the risk of needing additional funding, which could dilute existing shareholders.
What are the key factors to evaluate for IUGNF?
Evaluate IUGNF on fundamentals, analyst consensus, and risk factors. No dividend yield reflects the company's focus on reinvesting earnings into research and development. Not financial advice.
How frequently does IUGNF data refresh on this page?
IUGNF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven IUGNF's recent stock price performance?
Imugene Limited (IUGNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary immunotherapy technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IUGNF overvalued or undervalued right now?
Imugene Limited (IUGNF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research IUGNF before investing?
Before investing in Imugene Limited (IUGNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 7 from Financial Modeling Prep (FMP) and 10 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com